DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1590 De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis—has
the principle been proven? N Engl J Med, 2007, 356:409–411.
Dodgson AR, Dodgson KJ, Pujol C, et al. Clade-specific flucytosine
resistance is due to a single nucleotide change in the FURl
gene of Candida albicans. Antimicrob Agents Chemother, 2004,
48:2223–2227.
Evans EG, Sigurgeirsson B. Double blind, randomised study of
continuous terbinafine compared with intermittent itraconazole
in treatment of toenail onychomycosis. The LION Study
Group. BMJ, 1999, 318:1031–1035.
Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of
posaconazole in fasted healthy subjects. Clin Pharmacokinet,
2005, 44:211–220.
Fernandez-Obregon AC, Rohrback J, Reichel MA, et al. Current
use of anti-infectives in dermatology. Expert Rev Anti Infect
Ther, 2005, 3:557–591.
Frampton JE, Scott LJ. Posaconazole. A review of its use in the
prophylaxis of invasive fungal infections. Drugs, 2008,
68:99–1016.
Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis
and treatment of Candida infections. Expert Rev Anti-
Infect Ther, 2008, 6:153–162.
Greenberg RN, Mullane K, van Burik J-AH, et al. Posaconazole
as salvage therapy for zygomycosis. Antimicrob Agents
Chemother, 2006, 50:126–133.
Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of
isavuconazole (BAL4815), voriconazole, and fluconazole
against 1,007 isolates of Zygomycete, Candida, Aspergillus,
Fusarium and Scedosporium species. Antimicrob Agents
Chemother, 2008, 52:1396–1400.
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole
versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 2002, 347:408–415.
Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole.
Clin Ther, 2003, 25:1321–1381.
Johnson MD, Perfect JR. Caspofungin: First approved agent in
a new class of antifungals. Expert Opin Pharmacother, 2003,
4:807–823.
Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of
liposomal amphotericin B compared with conventional
amphotericin B for induction therapy of histoplasmosis in
patients with AIDS. Ann Intern Med, 2002, 137:105–109.
Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention
and treatment of opportunistic infections in adults and
adolescents. Recommendations from CDC, the National
Institutes of Health, the HIV Medicine Association of the
Infectious Diseases Society of America. MMWR Recomm Rep,
2009, 58:1–207.
Keating G, Figgitt D. Caspofungin: A review of its use in
oesophageal candidiasis, invasive candidiasis and invasive
aspergillosis. Drugs, 2003, 63:2235–2263.
Kim R, Khachikian D, Reboli AC. A comparative evaluation of
properties and clinical efficacy of the echinocandins. Expert
Opin Pharmacother, 2007, 8:1479–1492.
Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole
following single-dose oral administration in healthy subjects.
Antimicrob Agents Chemother, 2004, 48:3543–3551.
Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole
on the pharmacokinetics properties of oral and intravenous
midazolam: A phase 1, randomized, open-label,
SECTION VII
CHEMOTHERAPY OF MICROBIAL DISEASES
crossover study in healthy volunteers. Clin Ther, 2009a, 31:
286–298.
Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption
of posaconazole oral suspension under various gastric conditions
in healthy volunteers. Antimicrob Agents Chemother,
2009b, 53:948–966.
Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a
regimen of amphotericin B followed by fluconazole for candidaemia
in non-neutropenic patients: A randomized non-inferiority
trial. Lancet, 2005, 366:1435–1442.
Kuse E-R, Chetchotisakd P, daCunha CA, et al. Micafungin
versus liposomal amphotericin B for candidaemia and invasive
candidosis: A phase III randomized double blind trial.
Lancet, 2007, 369:1519–1527.
Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined
with flucytosine for treatment of cryptococcal meningitis in
patients with AIDS. Clin Infect Dis, 1994, 19:741–745.
Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin
and amphotericin B for invasive candidiasis. N Engl J
Med, 2002, 347:2020–2029.
Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole
on the pharmacokinetics of serolimus. Curr Med Res Opin,
2009, 25:701–707.
Odds FC. Drug evaluation: BAL-8577—a novel broad-spectrum
triazole antifungal. Curr Opin Investig Drugs, 2006, 7:766–772.
Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in
human immunodeficiency virus-negative patients in the era of
effective azole therapy. Clin Infect Dis, 2001, 33:690–699.
Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus
caspofungin for treatment of candidemia and other forms of
invasive candidiasis. Clin Infect Dis, 2007, 45:883–893.
Park S, Kelly R, Nielsen Kahn J, et al. Specific substitutions in
the echinocandin target Fks1p account for reduced susceptibility
of rare laboratory and clinical Candida sp isolates.
Antimicrob Agents Chemother, 2005, 49:3264–3273.
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice
guidelines for the management of cryptococcal disease: 2010
update by the Infectious Diseases Society of America. Clin
Infect Dis, 2010, 50:291–322.
Perkhofer S, Lechner V, Lass-Flörl C. In vitro activity of isavuconazole
against Aspergillus species and Zygomycetes according
to the methodology of the European Committee on
Antimicrobial Susceptibility Testing. Antimicrob Agents
Chemother, 2009, 53:1645–1647.
Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus
fluconazole for invasive candidiasis. N Engl J Med, 2007,
356:2472–2482.
Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole
therapy in allergic bronchopulmonary aspergillosis. Chest,
1999, 116:1665–1668.
Schmitt-Hoffman A, Roos B, Marres J, et al. Multiple dose pharmacokinetics
and safety of the new antifungal triazole
BAL4815 after intravenous infusion and oral administration
of its prodrug, BAL8557, in healthy volunteers. Antimicrob
Agents Chemother, 2006, 50:286–293.
Smith WJ, Drew RH, Perfect JR. Posaconazole’s impact on prophylaxis
and treatment of invasive fungal infections: An
update. Expert Rev Anti Infective Ther, 2009, 7:165–181.
Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analyses,
animal models, and 60 clinical cases of invasive Aspergillus